FM
ANIK icon

Fondren Management’s Anika Therapeutics ANIK Stock Holding History

Fondren Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-35,000
Closed -$1.12M – 76
2018
Q2 		$1.12M Buy
+35,000
New +$1.44M 0.86% 33

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fondren Management's ANIK Position: Q3 2018 in Review

Fondren Management sold out of Anika Therapeutics (ANIK) in Q3 2018, closing a stake of 35,000 shares — an estimated $1.12M sold.

Fondren Management first reported a position in ANIK in Q2 2018 and held it in 1 quarter. The position peaked at $1.12M in Q2 2018. 161 funds tracked by Wall St. Rank hold ANIK as of Q3 2018.

  • Fondren Management reported no remaining Anika Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Fondren Management sold 35,000 Anika Therapeutics shares in Q3 2018, an estimated $1.12M.
  • Fondren Management first reported a position in Anika Therapeutics in Q2 2018 and held it in 1 quarter.
  • Fondren Management's Anika Therapeutics position peaked at $1.12M in Q2 2018.
  • 161 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2018.

Based on Fondren Management's 13F filing for Q3 2018, filed 14 Nov 2018.